SELLAS Life Sciences Reports Positive Phase 3 Results for AML Therapy
· 6 sources
SELLAS Life Sciences (SLS) reported positive Phase 3 results for its leukemia therapy, and outlets cite a surge of roughly 236% to 240% in the stock.
What happened
SELLAS Life Sciences (SLS) reported positive Phase 3 trial results for its therapy for acute myeloid leukemia (AML), according to TipRanks. Seeking Alpha describes the result as a late-stage trial win for a cancer vaccine.
Investing.com and TipRanks report that the stock soared, citing gains of 240% and 236% respectively. Stocktwits reports that the CEO called the leukemia data bullish and said it could support recognition of the therapy, referred to as GPS, by the NCCN.
Earlier, Yahoo Finance reported that Susquehanna and Prudential added 1.3 million SLS shares in the third quarter, and that Prudential's stake grew nearly 24-fold. Yahoo Finance also noted retail interest in Lilly's cancer deal as a valuation reference.
Context
Phase 3 trials are the late-stage studies that typically precede regulatory review of a new therapy.
Why it matters
The trial outcome is a major event for SELLAS, a company whose value depends heavily on the progress of its leukemia program.
Stocks in this story
Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.
39%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $11.63 and $21.50; 9 in 10, between $6.74 and $37.08.
Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.
Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer
ATLAS Signals
ATLAS Signals, every week
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy